PUNE, India, March 4, 2020 /PRNewswire/ -- A recent report by Infinium Global Research's on the "Cardiac Biomarkers Market (Type - Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), and Other Types; Location of Testing - Point of Care Testing, and Laboratory Testing; Applications - Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Other Applications): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025" estimates that the market is projected to expand with a CAGR of 12.5% over the period of 2019 to 2025 and would be worth USD 14 Billion by 2025. The report also provides a comprehensive outline of the factors responsible for the growth of the market.
Cardiovascular diseases are the greatest cause of death over the globe. Nearly 634,000 people died of heart disease, making it the leading cause of death in 2015. As per the American Heart Association, about 28.2 million U.S. adults were diagnosed with heart disease as of 2016 and approximately every 40 seconds an American will have a heart attack. Over the last 50 years, cardiac biomarkers are being used for primary and secondary prevention, the diagnosis and management of acute myocardial infarction (AMI), and the diagnosis and risk stratification of heart failure (HF). They have evolved as essential tools in cardiology. Additionally, the rising emergence of novel biomarkers, increasing evidence supporting specific clinical uses of natriuretic peptides and increased emphasis on precision medicine have all contributed to the continued expansion of biomarker use in heart diseases.
Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/reports/sample-request/13335
The Demand for Troponins to Escalate Over the Forecast Period for the Diagnosis of Acute Coronary Syndrome
The use of a large number of cardiac biomarkers is becoming a routine in clinical diagnosis, differential diagnosis, risk stratification, and prognosis and guides the management of patients with suspected cardiovascular diseases. They are anticipated to cut the use of the electrocardiogram, echocardiography cardiac imaging, and clinical symptom assessment. In particular, cardiac troponins have become the cardiac markers of choice for patients with ACS and is generating the maximum revenue in the cardiac biomarkers market. Troponins are the most frequently ordered and most specific of the cardiac markers available commercially. The cTn assays have become the foundation in the diagnosis and risk stratification of ACS due to its high sensitivity and nearly absolute myocardial tissue specificity.
Furthermore, the use of circulating heart failure (HF) biomarkers in the design of clinical trials has seen exponential growth in the previous years. Starting with expansion in the clinical application of B-type natriuretic peptide (BNP) and its precursor N-terminal pro-BNP (NT-proBNP) followed by the emergence of an array of novel HF biomarkers emblematic of different pathophysiological links in HF, biomarker testing in HF promises to provide a better understanding of the diagnosis. In other areas of IVD (in-vitro diagnostic), the trend will continue for the development of rapid point of care (POC) devices to avoid the delays and cost of sending samples to laboratories.
The report on the "Cardiac Biomarkers Market" offers an in-depth analysis of the segments such as Type (Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), and Other Types) Location of Testing (Point of Care Testing, and Laboratory Testing) and Applications (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Other Applications).
Ongoing Clinical Trials to Facilitate the Launch of Novel Cardiac Biomarkers by the End of 2025
The global cardiac biomarkers market is temperately competitive with the presence of a limited number of large-scale vendors who compete with each other in terms of product differentiation, quality, price, distribution, innovation, and brand promotion. Roche Diagnostics Limited, Abbott Laboratories, bioMérieux SA, Johnson and Johnson, Olympus Corporation, Siemens Healthcare GmbH, and Tosoh Corporation are key players holding a substantial share in the market. The potential clinical benefits offered by these biomarkers for more rapid and accurate disease diagnosis, and potential reduction in size and duration of clinical drug trials, is increasing the interest and research into disease-related biomarkers.
However, the market is also characterized by the technological development of novel tests for CVD biomarkers. Several industrial players are focusing on the development of highly efficient cardiac biomarkers tests. Several biomarkers are in clinical trials and are being investigated for their potential use in helping to evaluate people for ACS. Additionally, ongoing advancements in the industry would result in the emergence of numerous novel cardiac biomarkers by the end of 2025. The report published by Infinium Global Research delivers insights into the leading players that have contributed greatly to the growth of the cardiac biomarkers market and also estimates the impact of product innovations in the global market.
North America to Be the Leading Revenue Making Region in the Global Cardiac Biomarkers Market
Geographically, North America is expected to dominate the market in terms of revenue in the global cardiac biomarkers market. The high incidence of cardiovascular diseases in North America and the rising popularity of PoC diagnostics in cardiac disease management is expected to contribute to the demand for cardiovascular disease diagnostics. Additionally, cardiac biomarker testing is standard in high-income countries and high spending on healthcare facilities in countries such as the U.S. and Canada continues to significantly support the growth of the North America cardiac biomarkers market. Asian country such as Japan is also estimated to hold a significant share in the market owing to the presence of a large number of elderly populations affected with CVD coupled with the availability of developed healthcare infrastructure.
However, the implementation of cardiac biomarkers in the diagnosis of diseases might be economically prohibitive in resource-poor settings and may present challenges to many low- and middle-income countries such as China and India where resources are constrained and the majority of the population receives care at hospitals without advanced cardiovascular services. Nevertheless, the current economic growth in these countries is likely to foster the growth of the market and facilitate the adoption of advanced technologies in the diagnosis of cardiovascular diseases by the mid-term.
Need Assistance? Send an [email protected] https://www.infiniumglobalresearch.com/reports/enquiry/13335
Global Cardiac Biomarkers Industry Coverage
Chapter - 1 Preface
- Report Description
- Research Methods
- Research Approaches
Chapter - 2 Executive Summary
- Cardiac Biomarkers Market Highlights
- Cardiac Biomarkers Market Projection
- Cardiac Biomarkers Market Regional Highlights
Chapter - 3 Global Cardiac Biomarkers Market Overview
- Market Dynamics
- Porter's Five Forces Analysis
- IGR-Growth Matrix Analysis
- Value Chain Analysis of Cardiac Biomarkers Market
Chapter - 4 Cardiac Biomarkers Market Macro Indicator Analysis
Chapter - 5 Global Cardiac Biomarkers Market by Type
- Myocardial Muscle Creatine Kinase (CK-MB)
- Troponins (T and I)
- Brain Natriuretic Peptide (BNPs) or NT-proBNP
- Ischemia Modified Albumin (IMA)
- Other Types
Chapter - 6 Global Cardiac Biomarkers Market by Location of Testing
- Point of Care Testing
- Laboratory Testing
Chapter - 7 Global Cardiac Biomarkers Market by Applications
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Other Applications
Chapter - 8 Global Cardiac Biomarkers Market by Region 2019-2025
- North America
Chapter - 9 Company Profiles and Competitive Landscape
- Competitive Landscape in the Global Cardiac Biomarkers Market
- Companies Profiles
- Beckman Coulter, Inc.
- Roche Diagnostics Limited
- Abbott Laboratories
- bioMérieux SA
- Johnson and Johnson
- Olympus Corporation
- Siemens Healthcare GmbH
- Tosoh Corporation
- F. Hoffmann-La Roche Ltd.
- PerkinElmer Inc.
- Other Companies
Browse in-depth TOC on "Cardiac Biomarkers Market"
Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes and non-profit/non-government organizations to meet their knowledge and information needs.
Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide the knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations and environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.
Mr. Shrikant Athavale
Infinium Global Research
Office No. 103 and 104,
Suratwala Mark Plazzo,
Email: [email protected]
Research Insight: https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-cardiac-biomarkers-market
Visit Our Web Site: https://www.infiniumglobalresearch.com
SOURCE Infinium Global Research